Cl[C:2]1[N:7]=[CH:6][C:5]([CH2:8][N+:9]2[C:14]([O-:15])=[C:13]([C:16]3[CH:21]=[CH:20][C:19]([C:22]#[N:23])=[CH:18][CH:17]=3)[C:12](=[O:24])[N:11]3[CH:25]=[CH:26][CH:27]=[CH:28][C:10]=23)=[CH:4][CH:3]=1.[ClH:29].[OH:30][NH3+:31].CC(C)([O-])C.[K+]>CS(C)=O.[Cl-].[Na+].O>[Cl:29][C:2]1[N:7]=[CH:6][C:5]([CH2:8][N+:9]2[C:14]([O-:15])=[C:13]([C:16]3[CH:21]=[CH:20][C:19]([C:22](=[NH:23])[NH:31][OH:30])=[CH:18][CH:17]=3)[C:12](=[O:24])[N:11]3[CH:25]=[CH:26][CH:27]=[CH:28][C:10]=23)=[CH:4][CH:3]=130 mg (0.08 mmol) of 1-[(6-chloro-3-pyridyl)methyl]-3-(4-cyanophenyl)-4-oxo-pyrido[1,2-a]pyrimidin-1-ium-2-olate (product of step 1) were dissolved in 2 ml DMSO. 13 mg (0.2 mmol) hydroxylammonium hydrochloride and 22 mg (0.2 mmol) potassium t-butoxide were added and the mixture was stirred at room temperature for 18 hours. The mixture was taken up with 10 ml of brine and extracted with ethyl acetate. The organic phases were dried with magnesium chloride and the solvent was removed under reduced pressure. The desired product was sufficiently pure without further purification (10 mg).